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Gaucher disease (GD; glucosylceramidosis) is caused by a deficient activity of the enzyme
glucocerebrosidase (GC). Clinical manifestations are highly variable and cannot be
predicted accurately on the basis of the properties of mutant GC. Analysis of secondary
abnormalities, such as elevated plasma levels of some hydrolases, may help to increase
insight into the complicated pathophysiology of the disease and could also provide useful
disease markers. The recent availability of enzyme supplementation therapy for GD
increases the need for markers as early predictors of the efficacy of treatment. We report the
finding of a very marked increase in chitotrisidase activity in plasma of 30 of 32 symptomatic
type 1 GD patients studied: the median activity being > 600 times the median value in
plasma of healthy volunteers. In three GC-deficient individuals without clinical symptoms,
only slight increases were noted. Chitotriosidase activity was absent in plasma of three
control subjects and two patients. During enzyme supplementation therapy, chitotriosidase
activity declined dramatically. We conclude that plasma chitotriosidase levels can serve as
a new diagnostic hallmark of GD and should prove to be useful in assessing whether
clinical manifestations of GD are present and for monitoring the efficacy of therapeutic
intervention.
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Abstract
Gaucher disease (GD; glucosylceramidosis) is caused by a defi-
cient activity of the enzyme glucocerebrosidase (GC). Clinical
manifestations are highly variable and cannot be predicted accu-
rately on the basis of the properties of mutant GC. Analysis of
secondary abnormalities, such as elevated plasma levels of
some hydrolases, may help to increase insight into the compli-
cated pathophysiology of the disease and could also provide
useful disease markers. The recent availability of enzyme sup-
plementation therapy for GDincreases the need for markers as
early predictors of the efficacy of treatment. Wereport the
finding of a very marked increase in chitotriosidase activity in
plasma of 30 of 32 symptomatic type 1 GDpatients studied: the
median activity being > 600 times the median value in plasma
of healthy volunteers. In three GC-deficient individuals without
clinical symptoms, only slight increases were noted. Chitotrio-
sidase activity was absent in plasma of three control subjects
and two patients. During enzyme supplementation therapy, chi-
totriosidase activity declined dramatically. Weconclude that
plasma chitotriosidase levels can serve as a new diagnostic hall-
mark of GDand should prove to be useful in assessing whether
clinical manifestations of GDare present and for monitoring
the efficacy of therapeutic intervention. (J. Clin. Invest. 1994.
93:1288-1292.) Key words: Gaucher disease * glucosylcerami-
dosis * chitotriosidase * enzyme therapy * acid phosphatase
Introduction
Gaucher disease (GD)' is characterized by accumulation of
glucosylceramide (glucocerebroside) in the lysosomes of mac-
rophages. This is due to an inherited deficiency in the activity
of glucocerebrosidase (GC), a lysosomal hydrolase ( 1 ). Accu-
mulation of lipid-laden macrophages results in hepatospleno-
megaly, bone lesions, and, less commonly, in neurological ab-
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1. Abbreviations used in this paper: AP, acid phosphatase 5b; GC, glu-
cocerebrosidase; GD, Gaucher disease; MU, methylumbelliferyl; SSI,
severity scoring index.
normalities. For the most frequent nonneuronopathic pheno-
type (type 1 ) no strict correlation has been established between
mutant genotypes, residual GCactivity, and clinical expression
of the disease ( 1, 2). Even among siblings sharing the same GC
genotype a striking difference in clinical symptoms may occur.
It has been claimed that one of the most frequent mutant GC
genotypes, homozygosity for the N370S mutation, is associated
with mild disease (3, 4). However, with this genotype, com-
pletely asymptomatic elderly individuals as well as severely af-
fected young patients have been described. The limited correla-
tion between genotype and phenotype suggests a more compli-
cated pathophysiology of the disease and hampers genetic
counselling. This has stimulated interest in secondary biochem-
ical abnormalities associated with clinical manifestations of
GD. Elevated plasma levels of acid phosphatase Sb (AP) are
traditionally considered to be the most prominent secondary
biochemical abnormality ( 1). Moderate increases in plasma
levels of f3-hexosaminidase, angiotensin converting enzyme,
and lysozyme have also been described (1). Recently enzyme
supplementation therapy with alglucerase has become avail-
able. Since alglucerase is extremely costly and clinical improve-
ment during enzyme supplementation therapy is slow (usually
requiring at least 3-6 mo of treatment) (5, 6), the search for
secondary biochemical abnormalities as possible early indica-
tors of response to treatment has become an issue of increasing
importance.
Here we report on an extreme elevation in chitotriosidase
activity in the plasma of type 1 GDpatients. The increased
plasma levels of this novel enzyme were studied in relation to
those of APand lysozyme. Its possible source was investigated.
The clinical significance of these findings with respect to diag-
nosis, disease severity, and the monitoring of the efficacy of
enzyme supplementation therapy is discussed.
Methods
All GDpatients studied ( 16 males and 16 females; 3-72 yr old) were
known to us either by contact with the Netherlands Gaucher Society or
by referral to the Academic Medical Center. The diagnosis of GDwas
based on deficient glucocerebrosidase activity in leucocytes and/or ur-
ine samples (7, 8). The clinical manifestations of 25 patients (11 males
and 14 females; 15-72 yr old) were classified as being mild, moderate,
or severe by using the modified severity scoring index (SSI) (9), which
is based on an assessment of the extent of liver, spleen, and bone in-
volvement and the severity of pancytopenia. Using the SSI, mild dis-
ease was present in 7 patients, moderate disease in 12 patients, and
severe disease in 6 patients. No patient had acute manifestations of the
disease. During family screening, three other individuals (one male and
two females; 71, 78, and 96 yr old) were found to have deficient GC
activity, but no clinical expression of GD. The control population con-
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sisted of 50 healthy volunteers (30 males and 20 females; 23-56 yr
old), all of whomwere found to have normal GCactivity.
EDTA plasma samples were obtained from freshly drawn blood
and immediately stored at -20'C.
Four patients were studied during therapy with intravenous alglu-
cerase (Ceredase", Genzyme Corp., Cambridge, MA) at a dose of 4
U/kg, three times a week.
Chitotriosidase activity was measured by incubating 5 ,d of EDTA
plasma with 100 ul of 0.022 mM4-methylumbelliferyl-fl-D-NN,N'-
triacetylchitotriose (4 MU-chitotrioside; Sigma Chemical Co., St.
Louis, MO) as substrate in citrate/phosphate buffer (0.1 /0.2 M), pH
5.2, at 370C. In GDpatients, samples were diluted 50X in demineral-
ized water before incubation. After 15 min the reaction was stopped
with 2 ml of 0.3 Mglycine/NaOH buffer, pH 10.6. Fluorescent 4-
methylumbelliferone was measured with a fluorimeter (Perkin-Elmer
Corp., Norwalk, CT) at 445 nm. Chitotriosidase activity in the super-
natant of cultured cells was measured by incubating 10 Ml of the super-
natant with 100 Ml of substrate mixture for 30 min. The enzyme activi-
ties were linear with time of incubation and amount of enzyme (data
not shown).
Lysozyme activity towards cell wall suspension of Micrococcus ly-
sodeikticus (Sigma Chemical Co.) was determined as described by
Morsky (10).
Acid phosphatase activity was measured using 4-methylumbelli-
feryl phosphate as substrate in the presence of 3 Mmercaptoethanol as
described by Chambers et al. ( 11).
Immunoprecipitation studies were performed with a rabbit anti-
serum to chitotriosidase (obtained after immunization of a rabbit with
the purified enzyme) or with anti-(lysozyme) antibodies (Zymed Labs.,
Inc., San Francisco, CA). Chitotriosidase was purified from the soluble
fraction of a detergent-free homogenate of type 1 Gaucher spleen by a
sequence of chromatographic steps, including chromatofocussing, gel
filtration, and isoelectric focussing. Antibodies were coupled to protein
A-Sepharose 4B beads, and an excess of the immobilized antibodies
was incubated with plasma for 1 h at room temperature. After centrifu-
gation, enzyme activities in the supernatants were measured as de-
scribed above.
Monocytes were prepared as follows: mononuclear cells were iso-
lated from citrated blood, diluted 1:1 with PBS, by Percoll density
gradient centrifugation ( 1.077 g/cm3, 18 min, 2,000 rpm). After two
washing steps, one in PBS supplemented with 0.38% sodium citrate
and one in autologous plasma, cells were resuspended in Percoll ( 1.063
g/cm3) and carefully layered on Percoll ( 1.074 g/cm3). After centrifu-
gation ( 18 min at 2,000 rpm), monocytes were collected from a band
on top of the gradient. The cells were washed and resuspended in cul-
ture medium (RPMI 1640 supplemented with L-glutamine and 10%
human ABserum). The monocyte preparations had a purity exceeding
85%as judged by Giemsa staining. Monocytes were cultured in plastic
petri dishes at a concentration of 4 X 105 cells/ml in 10 ml of culture
medium. During 20 d of culture, 1.8 ml of the culture supernatant was
collected daily and replaced by fresh medium. After centrifugation, the
supernatant was immediately frozen at -20°C.
Results
Fig. 1 shows the plasma levels of chitotriosidase, lysozyme, and
AP in 32 untreated symptomatic GDpatients (III), 3 asymp-
tomatic GC-deficient individuals (II), and 50 healthy controls
(I). Chitotriosidase activity was strikingly increased in 30 GD
patients (median, 12,824; range, 3,122-65,349 nmol/ml per
h) as compared with asymptomatic GC-deficient individuals
(90, 166, and 195 nmol/ml per h) and healthy controls (me-
dian, 20; range, 4-76 nmol/ml per h) (Fig. 1 A). In the 30 GD
patients chitotriosidase was increased 2 100-fold, the median
value being > 600 times the median value of the control sub-
jects. However, in two GDpatients, chitotriosidase activity was
almost absent (2 and 3 nmol/ml per h). Mixing experiments
indicated that the plasma samples of these patients contained
no inhibitors of the enzyme. In the three asymptomatic GC-de-
ficient individuals the elevation with respect to the median
control value was only 9.7, 4.5, and 8.3 times.
Since it is known that the 4 MU-chitotrioside substrate can
also be hydrolyzed by lysozyme ( 12), the contribution of this
enzyme to the observed chitotriosidase activity was assessed by
the measurement of the activity of lysozyme, using a suspen-
sion of cell walls of M. lysodeikticus as substrate. Lysozyme
activity, measured in 27 of the 32 GD patients, was only
slightly increased (median, 4.1; range, 1.3-9.5 U/,ul) as com-
pared with the controls (median, 1.7; range, 0.7-2.9 U/,ul) and
the asymptomatic individuals ( 1.2, 1.7, and 3.5 U/,ql). Interest-
ingly, in both GDpatients with low chitotriosidase activity,
elevations in lysozyme activity (4.1 and 5.0 U/Mgl) were similar
to those in the other GDpatients. Comparison of chitotriosi-
dase and lysozyme activities in the 30 GDpatients revealed no
correlation (r = 0. 15), indicating that the observed chitotriosi-
dase activity can not be explained by lysozyme activity. More
importantly, chitotriosidase activity in GDplasma samples
proved to be almost completely precipitable with anti-(chito-
triosidase) antiserum, but not at all with anti-(lysozyme) anti-
bodies. On the other hand, plasma lysozyme could not be im-
munoprecipitated with anti-(chitotriosidase) antiserum. In the
two GDpatients with very low chitotriosidase activities, im-
munoprecipitation with anti-(lysozyme) antibodies showed
that the low residual activity present was entirely due to lyso-
zyme. The same phenomenon was found in the three control
subjects with relatively low chitotriosidase activities (4, 4, and
6 nmol/ml per h) (data not shown).
AP activity was elevated to a variable extent in plasma of all
GDpatients (median, 2,590; range, 452-9,785 nmol/ml per h
in the 30 patients with high chitotriosidase activity; 1,159 and
4,764 nmol/ml per h in the 2 patients with low chitotriosidase
activity), when compared with controls (median, 202; range,
94-342 nmol/ml per h) and asymptomatic individuals (100,
130, and 177 nmol/ml per h). In GDpatients, the elevations in
AP activities were clearly far less prominent than those in chi-
totriosidase activities (Fig. 1, A and B).
In GDpatients, the macrophages are a likely cellular source
of biochemical abnormalities ( 1). We therefore studied the
production and secretion of chitotriosidase activity during dif-
ferentiation of cultured monocytes into macrophages. During
the first 5 d of culture of purified monocytes, chitotriosidase
activity was found to be absent both in the cells and superna-
tant. After morphological differentiation of monocytes into
macrophages, the cells began to produce and secrete increasing
amounts of chitotriosidase (Fig. 2). APwas also produced and
secreted after 5 d of culture (Fig. 2) (see reference 13).
Wedid not find a correlation between chitotriosidase levels
and the severity of clinical manifestations, as assessed by the
use of the SSI (data not shown). However, in asymptomatic
GC-deficient individuals only mild elevations were found. Like-
wise, chitotriosidase levels did not correlate with the mutant
GCgenotype in the GDpatients (data not shown).
Four patients were treated by enzyme supplementation
therapy for 2 1 yr. After 3-6 mo, clinical improvement was
apparent with respect to hematological markers and reduction
in organomegaly ( 14). Fig. 3, A-D, shows that chitotriosidase
levels rapidly declined during enzyme supplementation ther-
apy, starting already within 1-2 mo.




















































Chitotriosidase activity in plasma samples of untreated type 1
GDpatients was found to be strikingly elevated. Moreover,
chitotriosidase activity began to decline rapidly after the initia-
tion ofenzyme supplementation therapy. Previously, the occur-
rence of a chitotetraosidase activity in normal human plasma
has been reported ( 15 ). The chitotriosidase described here re-
sembles the plasma chitotetraosidase with respect to the appar-
ent basic isoelectric point and nonbinding to the lectin conca-
navalin A. It is therefore possible that chitotriosidase and chito-
tetraosidase activities are due to a single enzyme. An increase
in either chitotriosidase or chitotetraosidase activities in associ-










Figure 1. Levels of plasma chitotrio-
sidase (A), and lysozyme and AP
activity (B) in controls (I, n = 50),
asymptomatic GC-deficient individ-
uals (II, n = 3), and symptomatic
GDpatients (III, n = 32).
The increase in plasma chitotriosidase in GDpatients is far
more pronounced than the increase in AP activity, which has
often been used as an important diagnostic hallmark of the
disease ( 16, 17). Even in asymptomatic GC-deficient individ-
uals a slight elevation in chitotriosidase activity was found,
whereas in these individuals AP levels were well within the
control range. Because of the simplicity and sensitivity of the
assay, determination of chitotriosidase activity can conve-
niently be used for biochemical confirmation of the diagnosis
of GD, in addition to the demonstration of glucocerebrosidase
deficiency. Surprisingly, in two of the 32 GDpatients studied
we repeatedly found an almost complete absence of chitotriosi-
dase activity. In these cases residual enzyme activity was found
to be due to lysozyme, which also has catalytic activity towards


























Figure 2. Secretion of chitotriosidase (filled triangles) and AP (open
triangles) in medium of cultured monocytes during differentiation
into macrophages. Enzyme activities (means of a duplicate experi-
ment) are expressed in nmol/ml medium per h. Values were
corrected for the daily change in medium.
the 4-methylumbelliferyl substrate, although clearly distinct
from chitotriosidase. One of the parents of a chitotriosidase-de-
ficient GDpatient also lacked enzyme activity, suggesting a
familial nature of the deficiency. Absence of chitotriosidase
activity was also observed in 3 of 50 controls studied.
The question arises as to what the biological function of
chitotriosidase is. Since the two GDpatients lacking chitotrio-
sidase activity manifested characteristic clinical symptoms, it is
unlikely that chitotriosidase itself contributes to the clinical
presentation of GD. On the other hand, the similarity between















towards the same substrate suggests that chitotriosidase may
also have a function in host defense mechanisms, e.g., through
cleavage of bacterial cell wall polysaccharide.
Another important question relates to the source of chito-
triosidase. GDis characterized by the presence of large num-
bers of macrophages loaded with glucosylceramide. It therefore
seemed likely that these so-called "Gaucher cells" are the main
source of the plasma chitotriosidase activity. Our in vitro data
support the hypothesis that the enzyme is macrophage derived.
However, the rapid decline in chitotriosidase levels after the
start of enzyme supplementation therapy, preceding objective
clinical improvement, suggests that the production of chito-
triosidase is not a simple function of the number of lipid-laden
macrophages. This is also suggested by the poor correlation
between chitotriosidase levels and SSI, which mainly focusses
on the extent of organ involvement in GD. It is more likely that
in GDa particular state of activation or differentiation of mac-
rophages or of their precursors leads to the excessive produc-
tion of chitotriosidase. The rapid decrease in chitotriosidase
activity during supplementation with GCmay (initially) re-
flect an alteration in this state rather than a decrease in
Gaucher cell mass. The changes in chitotriosidase levels upon
enzyme supplementation therapy suggest that the enzyme can
be a promising parameter for assessing the clinical response to
treatment. More extended studies are needed to relate clinical
improvement to decrease in chitotriosidase levels.
Since activated macrophages contribute to the pathophysi-
ology of many diseases, chitotriosidase activity was determined
in plasma samples of a number of patients with granulomatous
immunological disorders (Wegener's granulomatosis, sarcoi-
dosis) or granulomatous infectious diseases (tuberculosis,
leishmaniasis, and leprosy). Elevated enzyme levels were only
found for some patients with leishmaniasis and sarcoidosis
B
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Figure 3. Decrease in plasma chito-
triosidase activity in time in four
type 1 GDpatients (A-D) treated
10 20 30 40 50 with alglucerase (50 U/kg per mo).
time (wk) (control range, 4-80 nmol/ml per h)


























(Hollak, C. E. M., and J. M. F. G. Aerts, manuscript in prepara-
tion). However, in these cases even the highest chitotriosidase
levels did not exceed 1,800 nmol/ml per h, being clearly less
than the lowest chitotriosidase activities found for symptom-
atic GDpatients. In plasma samples of patients with acute and
chronic myeloid leukemia (diseases that are commonly listed
in the differential diagnosis of GD) chitotriosidase activities
were within or slightly above the normal range.
It is of importance to note that chitotriosidase levels were
found to be only moderately increased in the asymptomatic
patients studied and > 100-fold in the mildly affected patients.
This difference is unique with respect to secondary markers
and suggests that increasing chitotriosidase levels can prove to
be a sensitive harbinger of clinical symptoms and consequently
may contribute to considerations concerning early therapeutic
intervention.
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